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S U M M A R Y
Objectives: To describe the detection, clinical presentation, and prognosis of West Bank and East
Jerusalem Palestinians infected with HIV/AIDS, and HIV testing patterns of Palestinians in the Jerusalem
area.
Design and methods: This was a case–control analysis comparing all 33 Palestinian HIV/AIDS patients
who were referred to the Hadassah AIDS Center (HAC) over 17 years (1994–2010) with 77 non-
Palestinian patients seen over the same period. The systematic sampling method was used to select the
control group. Patterns of HIV testing were observed for the years 2002 and 2007.
Results: Many Palestinian patients (36%) were diagnosed during their initial hospitalization, while 47.1%
of non-Palestinians were diagnosed as outpatients. Signiﬁcantly more opportunistic infections were
detected during diagnosis among Palestinians (48.5%) than among non-Palestinians (9.1%, p < 0.001).
Overall mortality among Palestinian patients was 36.4% (12/33) vs. 6.5% (5/77) among non-Palestinians
(p < 0.001). No signiﬁcant differences in the initial CD4 counts and viral load levels were noted between
Palestinians and non-Palestinians (256/mm3 and log 4.58 copies/ml vs. 271/mm3 and log 4.49 copies/ml,
respectively). Follow-up visits were more infrequent among Palestinians than among non-Palestinians:
9.8 ( 1.0) compared with 23.4 ( 12.9), respectively (p < 0.001), over a median follow-up of 2.7 years for
Palestinians and 8.1 years for non-Palestinians (p < 0.001). With regard to HIV testing, 7.3% (72/989) of
individuals tested in 2002 and 10.9% (202/1851) in 2007 were Palestinians. The most frequent reason for
being tested among Palestinians was ‘medical’ (e.g., before in vitro fertilization, 69.4% in 2007); among non-
Palestinians it was ‘intimate relationships’ (31% in 2007).
Conclusion: These results show that despite an overall small number of Palestinian HIV/AIDS patients,
late diagnosis and high mortality are very much in evidence.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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According to the UNAIDS estimates for 2008, the number of
people infected with HIV and living in the Middle East and North
Africa was 310 000 (250 000–380 000).1 In 2007, the estimated
numbers of HIV-positive individuals in Arab countries neighboring
Israel were 9200 for Egypt, 1000 for Jordan, and 3000 for Lebanon.
While no HIV statistics were available for the Palestinian
Authority, Israel reported 5100 HIV-positive patients.2–4 A single
1993 report on HIV/AIDS among Palestinian blood donors5
suggested that a situation of under-diagnosis/under-reporting* Corresponding author.
E-mail address: ayelet.rosenthal@gmail.com (A. Rosenthal).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.12.012may exist in theWest Bank and Gaza. No other publications on the
topic have appeared in the last 15 years.
HIV testing patterns of Palestinians were observed at the
Jerusalem voluntary counseling and testing (VCT) clinic. For many
years, the Hadassah AIDS Center (HAC) has served as the reference
AIDS center for the Palestinian Authority (PA), mainly for patients
residing in the central and southernpart of theWestBank (including
Ramallah, Jericho, Bethlehem, and Hebron). Palestinians from other
parts of the PAhave often been referred toHIV clinics in other Israeli
hospitals. HIV-positive Palestinians in East Jerusalem, not under
Palestinian Ministry of Health (MOH) jurisdiction, were self-
referred, or referred by their general practitioners. The VCT clinic,
situatedwithinwalkingdistance of East Jerusalem,was the onlyHIV
testing clinic in the Jerusalem area offering free HIV testing.
Palestinian HIV/AIDS patients, under the Palestinian MOH
jurisdiction, were referred to the HAC by the PA or wereses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Reasons for diagnosis of HIV infection in (A) Palestinian and (B) non-
Palestinian patients at the Hadassah AIDS Center, 1994–2010.
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the West Bank, during hospitalization.
The objective of this study was to describe the clinical course
and prognosis of HIV/AIDS among Palestinian residents of theWest
Bank and East Jerusalem who were referred to the HAC.
Methods
All Palestinian HIV/AIDS-positive patients who were seen over
17 years (1994–2010) and who resided in the West Bank or East
Jerusalem were included in the analysis. A proportion of
approximately 1:2 Palestinian:non-Palestinian HIV-positive
patients was chosen for the case–control analysis. Sample size
determination was based on the expected difference in the
proportion of Palestinians (40%) and non-Palestinians (15%)
initially diagnosed during hospitalization, with a signiﬁcance level
of 5% (one-tailed) and a power of 80%; this calculation yielded a
total of 84 patients (at least 28 Palestinians and 56 non-
Palestinians). Eventually more patients were included. Non-
Palestinian patients were sampled using a systematic sampling
method.6
For the HIV testing patterns, Palestinian residents of East
Jerusalem and the West Bank, as well as Israeli Arabs living in the
Jerusalem area, were included. Two years of HIV testing, with an
interval of 5 years (2002 and 2007), were selected for analysis. Each
person answered a standardized routine questionnaire at the clinic
before being tested, and all of the questionnaires were analyzed.
For HIV testing at the clinic, a microparticle enzyme immunoassay
(MEIA) was used for the qualitative detection of antibodies to HIV-
1 and/or HIV-2 (AxSYM HIV 1/2 gO, Abbott). Western Blot was
done as a conﬁrmatory test.
To test the association between two categorical variables, the
Chi-square test and the Fisher’s-exact test were applied. For
comparison of quantitative variables between the two groups, the
independent samples t-test and theMann–Whitney non-paramet-
ric test were used.
Results
During the 17 years of observation, the median follow-up time
for Palestinian patients was 2.7 years and for the non-Palestinian
patients was 8.1 years (p < 0.001, Table 1).
Thirty-three Palestinian patients were seen at the HAC during
the period 1994–2010. No other knownHIV-positive patients were
diagnosed in the central and southern West Bank regions during
that period. The control group at the HAC clinic consisted of 77
non-Palestinian patients. The female:male ratio was 1:3.7 (21.2%
female, 78.8% male) among Palestinians and 1:1.5 (40.3% female,
59.7% male) among non-Palestinians (p = 0.05). The median age of
the Palestinian patients was 32 years and for non-Palestinian
patients was 33 years (non-signiﬁcant). Six out of 7 of the HIV-
positive Palestinian women in our analysis were married and wereTable 1
Demographic, clinical and prognostic data for the Palestinian and non-Palestinian pati
Mean
Age at diagnosis (years) Palestinians 35
Non-Palestinians 35
Duration of follow-up (years) Palestinians 4.36
Non-Palestinians 7.90
CD4 at diagnosis (/mm3) Palestinians 334
Non-Palestinians 313
Log VL at diagnosis (copies/ml) Palestinians 4.50
Non-Palestinians 4.19
VL, viral load.diagnosed following the diagnosis of their husbands, and none
belonged to established risk behavior groups for HIV.
Over the 17 years of follow-up, the average ( standard
deviation) number of follow-up visits for Palestinian patients was 9.8
( 1.0), and for non-Palestinians was 23.4 ( 12.9, p < 0.001).
Detection of HIV
Of the Palestinian patients, 36% (n = 9/25) were diagnosed
during their initial hospitalization in the West Bank, East
Jerusalem, or Israeli Jerusalem hospitals. Most non-Palestinians
(n = 33/70, 47.1%) were diagnosed as outpatients, mainly during
HIV screening of Ethiopian immigrants (Figure 1).
Initial CD4 count and HIV viral load (VL)
Non-signiﬁcant differences were noted in the median CD4
(p = 0.68) and VL counts (p = 0.5) between the Palestinian andents attending the Hadassah AIDS Center










Figure 2. All opportunistic infections (OI) presented during diagnosis and follow-up in Palestinian and non-Palestinian patients in the Hadassah AIDS Center, 1994–2010.
Signiﬁcant differences were found in the frequency of Pneumocystis pneumonia as the initial presenting OI (p = 0.001).
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mm3 and log 4.49 copies/ml, respectively, Table 1). Ethiopians
comprised a majority of the control group (55/77, 71.4%). Their
median CD4 was 268/mm3; CD4 among non-Ethiopian controls
was 337/mm3 (p = 0.22).
Clinical presentation
Signiﬁcantly more opportunistic infections (OIs) were detected
at diagnosis among Palestinian patients (16/33, 48.5%) as
compared to non-Palestinians (7/77, 9.1%) (p < 0.001). Signiﬁcant
differences were also found in the frequency of Pneumocystis
pneumonia as the initially presenting OI (p = 0.001; Figure 2).
Mortality
During the observation period, the mortality rate among
Palestinian patients was 36.4% (12/33) as compared to 6.5% (5/
77) for non-Palestinians (p < 0.001). Information regarding the
reasons for death among Palestinians was lacking for most cases,
but the death was veriﬁed with Palestinian doctors who referred
patients to the HAC.
HIV testing at the Jerusalem VCT clinic
Of the individuals tested in 2002, 7.3% (72/989) were Palesti-
nians; 73.6% (53/72) weremales and 26.4% (19/72) females. Similar
proportionswerenoted in the2007analysis: 10.9% (202/1851)were
Palestinians; 63.4% (128/202) males and 36.6% (74/202) females.
Based on ofﬁcial statistics, the Palestinian population in Jerusalem
comprised 32.0% of the total in 2002 and 34.4% in 2007.7,8Table 2
Reasons for taking an HIV test (in %) as determined by analyzing routine questionnaires;
cases, multiple reasons for testing were given by one person)
Reason for taking the test Palestinians
2002 (N=72) 2007 (N=202)
Any medical reason 54 69
Intimate relationship 4 9
Unsafe sex 11 8
Drug use 11 3
Routine test 10 12
Visa request 4 2
Other reason 13 7
VCT, voluntary counseling and testing clinic.The most frequent reason for being tested among Palestinians
in 2002 was indicated as ‘medical’, e.g. preceding an in vitro
fertilization procedure (54.3%). Among non-Palestinians it was
indicated as ‘intimate relationship’ (28%). In 2007, the trends
remained similar. The differences in the reasons: ‘medical’,
‘intimate relationship’, ‘unsafe sex’, and ‘routine’ were statistically
signiﬁcant when comparing Palestinians with non-Palestinians
(p < 0.001; Table 2).
An analysis of the reasons for testing by gender in 2002 and
2007 showed that among Palestinian females the most frequent
reason given was ‘medical’ (84.2%), as compared to ‘intimate
relationship’ (30.6%) among non-Palestinians. Among Palestinian
men, the most frequent reason was ‘medical’ (43.1%), while that
among non-Palestinians was ‘intimate relationship’ (25.4%).
Discussion
The striking ﬁndings of our analysis of this small cohort of
Palestinian patients are the high frequency of opportunistic
infections, the high overall mortality, and the frequent initial
diagnosis of HIV/AIDS found during hospitalization for opportu-
nistic infection. This pattern of presentation and the association
with a high mortality is similar to the pattern that was observed in
the early days of the AIDS epidemic.9–11 A similar pattern of late
detection and high mortality was observed in an analysis of a
similar Palestinian population some 15 years ago.5
The small number of patients in this cohort comes from a
catchment area that covers most of the West Bank population.
Thus, it may represent the tip of an iceberg of HIV carriers masked
by under-diagnosis and continued unapparent HIV transmission. It
is noteworthy that the estimated number of HIV carriers inPalestinian vs. non-Palestinian clients at the Jerusalem VCT 2002 and 2007 (in some
Non-Palestinians
p-Value 2002 (N=917) 2007 (N=1649) p-Value
0.023 23 29 0.001
0.195 28 31 0.093
0.406 22 24 0.269
0.007 8 4 <0.001
0.624 24 22 0.299
3.31 1 2 0.232
0.102 5 5 0.896
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double that of the West Bank.4
Of note is the lack of free systematic HIV testing for the general
West Bank population (VCT clinics). HIV screening is only done at
West Bank blood banks.12
Scarce information is available on HIV/AIDS in the Palestinian
population, this being the ﬁrst report in 15 years on the subject. The
Jerusalemareawaschosen foranalysisbecauseof theaccessibility to
antiretroviral treatment (ART) and VCT clinics for a large Palestinian
population in East Jerusalem, and the position of the HAC, which for
over 20 years has served as a referral center for the Palestinian
Ministry of Health (MOH) for HIV/AIDS. Since no CD4 and VL testing
is available in the West Bank at present, testing would normally be
done at the Hadassah hospital. New HIV-positive patients would
regularly be referred to theHAC for consultation, for the initiation of
ART, and for follow-up. A small group ofWest Bank physicians, who
are assigned by the Palestinian MOH, would follow HIV-positive
patients. Antiretroviral drugs purchased by the PA are available for
patients, in accordance with the initial HAC recommendations, at
one central pharmacy in Ramallah.
Prior to the establishment of the PA, close collaboration existed
between the PalestinianMOH and the HAC. Following consultation
with the HAC, Palestinian patients were among the ﬁrst to receive
antiretroviral drugs in the Arab world.12
A HAC–PA collaborative project on the prevalence of HIV/AIDS
in the general Palestinian population was successfully carried out
in 1994. HIV screening of 1300 healthy pregnant Palestinian
women in the delivery rooms of several West Bank hospitals was
carried out, with analysis of specimens performed at Hadassah
laboratories. HIV prevalence was found to be 0%.9 Following the
establishment of the PA, this collaboration has diminished and is
currently strictly limited to patient referral and care.12
HIV denial in a traditional Muslim society13 may signiﬁcantly
contribute to under-diagnosis. The lingering Israeli–Palestinian
conﬂict, which creates administrative barriers for proper follow-up
of patients, is a likely contributing factor to the overall picture.
Additionally, a conservative traditional Muslim society makes it
difﬁcult to break taboos around issues of sexual behavior.13
Although homosexuality is severely stigmatized,1 bisexuality
appears to be prevalent among homosexual men. A signiﬁcant
percentage of homosexual men report having injected drugs or
having engaged in sexual relations with at least one sex
worker.14,15 A single survey from Egypt in 2006 found that 6.3%
of homosexuals were HIV-seropositive.14
Previous reports have suggested a link between Islam and
tradition, and the low prevalence of HIV/AIDS in the Arab
population.13 A comparative analysis of HIV prevalence in African
countries suggested a negative connection between the prevalence
of HIV and the proportion of Muslims in the population. The link
between Muslims and sexual risk factors was found to be
variable.16
Access to educationalmaterial in Arabic about safe sex, sexually
transmitted diseases, and HIV prevention in the PA is limited. In
Middle Eastern Arab countries, sexual and reproductive health
remains a controversial subject. Indeed, there are few national
government programs addressing young people’s sexual and
reproductive health.17
Our analysis of HIV testing among Palestinians suggests a
signiﬁcantly lower proportion of the general Palestinian popula-
tion in East Jerusalem who use the Jerusalem VCT clinic for HIV
testing, compared with non-Palestinians. This, in addition to the
most common reason given for taking the test (medical/obligato-
ry), suggests that Jerusalem area Palestinians under-utilize the
Jerusalem VCT site as part of an AIDS prevention scheme.
We also noticed a difference in HIV testing patterns between
Palestinian and non-Palestinian women. The most frequent reasongiven by Palestinian women for testing was ‘medical/obligatory’,
signiﬁcantly higher than among non-Palestinian women
(p < 0.001).
The age–sex distribution of HIV in the Middle East suggests that
women are infected at a much younger age than men, since young
women are oftenmarried to oldermen, who aremore likely to have
been exposed to infection.18–20 This unfortunate pattern has also
been observed in sub-Saharan Africa.21 In our study, however, the
averageageatdiagnosisofPalestinianHIV-positivemenandwomen
was fairly similar – 28 years for women compared to 33 for men.
The Israeli–Palestinian conﬂict probably has some negative
effects on the access to medical care of Palestinian patients in
general. Its relevance to the small number of already diagnosed
Palestinian AIDS patients remains elusive.12 Anecdotal reports
suggest that Palestinian patientswho seekmedical care at the HAC,
need to go through cumbersome administrative procedures, both
on the Palestinian and the Israeli sides, in order to obtain entrance
permits to the HAC. These procedures probably affect the
consistency and quality of follow-up visits.
According to Physicians for Human Rights in Israel, entry of
medical supplies and exit of patients and medical personnel is
prohibited without special Israeli authorization. In the past two
years, there has been an ongoing decline in Israel’s permit granting
policy.22
In conclusion, although based on a very small number of
patients which may not be representative, our data showing late
diagnosis and a highmortality rate amongHIV-positive Palestinian
patients suggest that the Palestinian Authority’s AIDS control
program needs to be fortiﬁed. HIV screening clinics should be
made available to the general population. Access for women to
promotional material on HIV prevention should be allowed and
welcomed. There is an urgent need for the establishment of at least
one immunology and virology laboratory for CD4 and HIV viral
load determinations, and for the training of ART physicians. Based
on 20 years of experience, reliance on the Hadassah expert system
for AIDS care among Palestinians appears to be inadequate and
certainly needs to be reevaluated.
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